- Decreasing working population in Japan
- Climate change and other environmental issues
- OPDIVO patent expiration
- Diminishing success rate of drug discovery
- Need to develop new businesses beyond prescription drugs
ONO Pharmaceutical Co., Ltd.
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2021 | 23.6 thousand t-CO2 (Scope 1+2, market-based) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Brought forward the target date for reducing greenhouse gas emissions to zero from FY2050 to FY2035; set new targets to achieve carbon neutrality by FY2025 and to use eco-friendly paper materials for individual product packaging boxes by FY2030.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Achieve carbon neutrality by FY2025
- Use eco-friendly paper materials for individual product packaging boxes by FY2030
- Increase percentage of female managers to 10% by FY2026
📅 Medium-term
- Reduce greenhouse gas emissions to zero by FY2035
- Increase percentage of female managers to 20% by FY2031
- Have at least two or three OPDIVO successor drugs on the market by FY2031
🔭 Long-term
- Fulfill long-term vision of becoming a Global Specialty Pharma by FY2031; achieve 200 billion yen in annual R&D spending by FY2031
🌱 ESG Focus Areas
Environmental SustainabilityHuman Capital DevelopmentDigital Transformation (DX)GovernanceCompliance